FDA pushes back Ascendis' PDUFA for long-acting hormone therapy; Debiopharm takes home a ...

Retrieved on: 2021-06-14 15:22:30

Tags for this article:

Click the tags to see associated articles and topics

FDA pushes back Ascendis' PDUFA for long-acting hormone therapy; Debiopharm takes home a .... View article details on hiswai:

Excerpt

Danish biotech Ascendis Biopharma has been working on a treatment for pediatric growth hormone deficiency, but the FDA says they're going to have ...

Article found on: endpts.com